Dr. Bray Links

Thursday, January 25, 2018

New Stroke Treatment Guidelines - What's Hot at ISC 2018?

DEFUSE 3: This National Institutes of Health–funded trial is looking to expand the therapeutic window for thrombectomy out to 16 hours from time of stroke onset. "The DEFUSE 3 trial is seen as complementary to the recently reported DAWN trial, which showed a benefit of thrombectomy when used out to 24 hours in patients selected by clinical mismatch," Dr Ovbiagele commented. "DEFUSE differs in that the patients were selected for inclusion using imaging techniques to identify those who had a large potentially salvageable area of brain. It will be interesting to see if the results are different with these different ways of selecting patients."  


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.